Myriad™ Augmented Soft Tissue Reconstruction Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-10

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions

NCT05477225

Hidradenitis Suppurativa

UNKNOWN PHASE4

Use of the Amniotic Membrane in Large Wound Epithelialization

NCT01824381

Wounds

COMPLETED PHASE1

A Study to Evaluate the Efficacy of Microlyte Matrix in the Management of Donor Site Wounds

NCT05439746

Wounds and Injuries

UNKNOWN NA

Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds

NCT01948934

Wound

COMPLETED PHASE1

MIRODERM™ for Complex Wounds in an Inpatient Setting (MIRODERM CLOSure)

NCT02732548

Complex Wound

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational, multi-center, single arm, Phase IV study, designed to evaluate the safety and clinical outcomes of Matrix and Morcells in soft tissue reconstruction procedures.

The study is a registry study and will enroll participants who are undergoing a surgical procedure, and where the attending physician will use Myriad Matrix™ and/or Morcells™ as part of the surgical intervention.

Participants enrolled in the study will be undergoing a range of surgical procedures involving the reconstruction of soft tissues, including but not limited to:

* Abdominal dehiscence
* Necrotizing soft tissue infection (NSTI)
* Lower extremity complex non-healing wounds (limb salvage)
* Pilonidal sinus disease
* Anal fistula
* Hidradenitis suppurativa reconstruction
* Pressure injury reconstruction

Other procedure types may be included at the discretion of the Investigator/Research Team.

Participants that are being enrolled in the study would otherwise be undergoing their surgical procedure with either of the Myriad™ devices as part of Standard of Care (SoC).

The pre-operative care and preparation of the surgical site (prior to the application of Myriad™ devices) shall be undertaken at the discretion of the attending physician and per their institutional protocols and procedures. Surgical technique for the participants reconstruction is at the discretion of the attending physician. Use of Myriad Matrix™ or Morcells as part of the surgery shall be per the products Instructions for Use. Myriad Matrix™ devices may be implanted or used for dermal regeneration as part of the participants surgical procedure. Myriad Morcells™ may be used for dermal regeneration and in combination with the Myriad Matrix™ devices. The participants post-operative care is at the discretion of the attending physician.

Early and late-stage healing outcomes will be assessed as part of the study and as part of standard of care.

Through the course of treatment and following up care de-identified patient data (quantitative qualitative assessment measures and digital images) will be captured and from the basis of the registry dataset.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Wound Dehiscence Necrotizing Soft Tissue Infection Lower Extremity Wound Pilonidal Sinus Anal Fistula Hidradenitis Suppurativa Pressure Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Myriad™

Ovine forestomach matrix sheet graft and morselized extracellular matrix

Myriad Matrix™ and Myriad Morcells™

Intervention Type DEVICE

Ovine forestomach matrix sheet graft and morselized extracellular matrix

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myriad Matrix™ and Myriad Morcells™

Ovine forestomach matrix sheet graft and morselized extracellular matrix

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to provide written informed consent and to comply with the requirements of Clinical Investigational Plan
* Male or female patients aged 18 years or above
* Patients where Matrix and/or Morcells were used as part of their soft tissue reconstruction procedure
* Subject that are willing and able to comply with all aspects of the treatment and evaluation schedule

Exclusion Criteria

* Patients with known sensitivity to ovine (sheep) derived material
* Patients with full thickness ('third degree') burns
* Patients with wounds with uncontrolled clinical infection (CDC Contamination Grade=4)
* Any medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the patient to participate in the study
* Patient is currently participating or has participated in another clinical study within past 30 days prior to enrollment
* Pregnant or lactating women
* Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tracee Short, MD

Role: STUDY_CHAIR

Short Consulting Group, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Surgery Group LA

Los Angeles, California, United States

Site Status COMPLETED

Associates in Medicine & Surgery

Fort Myers, Florida, United States

Site Status ACTIVE_NOT_RECRUITING

Asencion Sacred Heart

Pensacola, Florida, United States

Site Status RECRUITING

Northeast Georgia Medical Center, Inc.

Gainesville, Georgia, United States

Site Status RECRUITING

University Medical Center

New Orleans, Louisiana, United States

Site Status RECRUITING